# Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation

> **NCT02741856** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Lisette Nixon** · enrollment: 584 (estimated)

## Conditions studied

- Oesophageal Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02741856
- **Lead sponsor:** Lisette Nixon
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11-04
- **Primary completion:** 2021-04
- **Final completion:** 2023-04
- **Target enrollment:** 584 (ESTIMATED)
- **Last updated:** 2018-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02741856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02741856, "Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02741856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*